Intravitreal metoprolol for circumscribed choroidal hemangiomas: a phase I clinical trial.
Angiogenesis Inhibitors
/ therapeutic use
Bevacizumab
/ therapeutic use
Choroid Neoplasms
/ diagnosis
Choroidal Neovascularization
/ drug therapy
Fluorescein Angiography
Follow-Up Studies
Hemangioma
Humans
Intravitreal Injections
Metoprolol
/ therapeutic use
Pilot Projects
Tomography, Optical Coherence
Choroid
Electroretinogram
Hemangioma
Metoprolol
Ocular toxicity
β-blocker
Journal
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
ISSN: 1435-702X
Titre abrégé: Graefes Arch Clin Exp Ophthalmol
Pays: Germany
ID NLM: 8205248
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
16
10
2020
accepted:
09
03
2021
revised:
17
01
2021
pubmed:
30
4
2021
medline:
25
8
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
Choroidal hemangioma is a visual threatening condition for which treatments is neither uniform nor widely available. New management options are necessary. The purpose of this study is to assess the safety and early outcome of intravitreal metoprolol tartrate in five patients with CCH. Five eyes of five patients diagnosed with subfoveal or peripapillary CCH and unsuccessfully treated with intravitreal anti-VEGF agents were enrolled and received off-label intravitreal injections of metoprolol (50μg/0.05 ml). Baseline and follow-up evaluations included best-corrected visual acuity, intraocular pressure measurement, assessment of anterior chamber cellular score/flare and vitritis, retinography, fundus autofluorescence, and ERG. Patients were followed for a period of 30 days. Statistical analysis involved comparison of pre- and post-treatment findings using a paired t-test. There was no significant difference in all ERG parameters regarding a- and b-wave amplitude and implicit time, and oscillatory potentials' maximal amplitude. There were no significant changes in visual acuity. None of the patients developed clinical signs of intraocular inflammation. The subretinal and/or intraretinal fluid improved in 3 out of 5 patients 4 weeks after the metoprolol injection. Patients with CCH treated with a single injection of 50μg/0.05ml intravitreal metoprolol injections showed no signs of acute ocular toxicity. This pilot study did not assess long-term retinal toxicity, different concentrations, drug resistance, and complications from repeated-intravitreal injections.
Sections du résumé
BACKGROUND
BACKGROUND
Choroidal hemangioma is a visual threatening condition for which treatments is neither uniform nor widely available. New management options are necessary. The purpose of this study is to assess the safety and early outcome of intravitreal metoprolol tartrate in five patients with CCH.
METHODS
METHODS
Five eyes of five patients diagnosed with subfoveal or peripapillary CCH and unsuccessfully treated with intravitreal anti-VEGF agents were enrolled and received off-label intravitreal injections of metoprolol (50μg/0.05 ml). Baseline and follow-up evaluations included best-corrected visual acuity, intraocular pressure measurement, assessment of anterior chamber cellular score/flare and vitritis, retinography, fundus autofluorescence, and ERG. Patients were followed for a period of 30 days. Statistical analysis involved comparison of pre- and post-treatment findings using a paired t-test.
RESULTS
RESULTS
There was no significant difference in all ERG parameters regarding a- and b-wave amplitude and implicit time, and oscillatory potentials' maximal amplitude. There were no significant changes in visual acuity. None of the patients developed clinical signs of intraocular inflammation. The subretinal and/or intraretinal fluid improved in 3 out of 5 patients 4 weeks after the metoprolol injection.
CONCLUSIONS
CONCLUSIONS
Patients with CCH treated with a single injection of 50μg/0.05ml intravitreal metoprolol injections showed no signs of acute ocular toxicity. This pilot study did not assess long-term retinal toxicity, different concentrations, drug resistance, and complications from repeated-intravitreal injections.
Identifiants
pubmed: 33914160
doi: 10.1007/s00417-021-05153-9
pii: 10.1007/s00417-021-05153-9
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Metoprolol
GEB06NHM23
Types de publication
Clinical Trial, Phase I
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2837-2841Subventions
Organisme : Conselho Nacional de Desenvolvimento Científico e Tecnológico
ID : 305299/2018.
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Casini G, Monte MD, Fornaciari I, Filippe L, Badnoli P (2014) The β-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res 42:103–129. https://doi.org/10.1016/j.preteyeres.2014.06.001
doi: 10.1016/j.preteyeres.2014.06.001
pubmed: 24933041
Karimi S, Nikkhah H, Ahmadieh H, Safi S (2018) Intravitreal injection of propranolol for the treatment of retinal capillary hemangioma in a case of Von Hippel Lindau. Retin Cases Brief Rep 14:305–309. https://doi.org/10.1097/ICB.0000000000000718
doi: 10.1097/ICB.0000000000000718
Jorge R, Chaves L, Cunha AS, Correa ZM (2019) Alternative management of circumscribed choroidal hemangioma using intravitreal metoprolol. Retin Cases Brief Rep 10. https://doi.org/10.1097/ICB.0000000000000917 .
American Society of Health-System Pharmacists (2018) Handbook on Injectable Drugs. 20
Cheong HI, Johnson J, Cormier M, Hosseini K (2008) In vitro cytotoxicity of eight beta-blockers in human corneal epithelial and retinal pigment epithelial cell lines: comparison with epidermal keratinocytes and dermal fibroblasts. Toxicol in Vitro 22:1070–1076. https://doi.org/10.1016/j.tiv.2008.01.013
doi: 10.1016/j.tiv.2008.01.013
pubmed: 18316173
Fraunfelder FT, Fraunfelder FW, Chambers WA (2015) Drug-induced ocular side effects. Clinical Ocular Toxicology. 7th edition. Saunders, p17.
McCulloch DL, Marmor MF, Brigell MG, Hamilton R, Holder GE, Tzekov R, Bach M (2015) ISCEV Standard for full-field clinical electroretinography (2015 update). Doc Ophthalmol 130:1–12. https://doi.org/10.1007/s10633-014-9473-7
doi: 10.1007/s10633-014-9473-7
pubmed: 25502644
Nourinia R, Rezaei Kanavi M, Kaharkaboudi A et al (2015) Ocular safety of intravitreal propranolol and its efficacy in attenuation of choroidal neovascularization. Invest Ophthalmol Vis Sci 56:8228–8235. https://doi.org/10.1167/iovs.15-17169
doi: 10.1167/iovs.15-17169
pubmed: 26720475
pmcid: 5110239
De Paiza MRB, Arribada RG, da Silva CN, Ribeiro MCS, Jorge R, Fialho SL, Cunha AS (2020) Assessment of the safety of intravitreal injection of metoprolol tartrate in rabbits. Doc Ophthalmol 142(1):75–85. https://doi.org/10.1007/s10633-020-09781-0
doi: 10.1007/s10633-020-09781-0
Augsburger JJ, Shields JA, Moffat KP (1981) Circumscribed choroidal hemangiomas: long-term visual prognosis. Retina 1:56–61
pubmed: 15633407